Clinical Trials Logo

Clinical Trial Summary

STA-9090, a synthetic small molecule, demonstrates significant activity for down-regulating Heat Shock Protein 90 or Hsp90 levels. Hsp90 belongs to a class of molecular chaperone proteins known to be critical regulators of cancer cell proliferation and survival. Preclinical laboratory experiments have shown STA-9090, an Hsp90 inhibitor, could inhibit ocular melanoma cell lines. The primary objective of this trial is to obtain evaluations of STA-9090 efficacy to metastatic ocular melanoma.


Clinical Trial Description

Patients with metastatic ocular melanoma have a poor prognosis and very limited standard therapeutic options. The recent discoveries of GNAQ and GNA11 mutations leading to MAPK pathway activation and the over-expression of c-Met generate the hypothesis that inhibition of hsp90 client proteins will provide clinical benefit. This study tests the feasibility and efficacy of hsp90 inhibition in patients with metastatic ocular melanoma. Multiple components of the MAPK pathway (B-Raf, C-Raf, cdk4) in addition to c-Met are client proteins of hsp90 and dependent of active hsp90 for stability. Inhibition of hsp90 should lead to decreased expression of these client proteins. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01200238
Study type Interventional
Source Dana-Farber Cancer Institute
Contact
Status Completed
Phase Phase 2
Start date September 17, 2010
Completion date November 11, 2016

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04364230 - Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) Phase 1/Phase 2
Active, not recruiting NCT02858869 - Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases Phase 1
Completed NCT01355120 - THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease Phase 2
Recruiting NCT05524935 - Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma Phase 2
Recruiting NCT05628883 - Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma Phase 1
Active, not recruiting NCT05187884 - Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma Phase 2
Recruiting NCT02909517 - The Role of Inflammation in Ocular Tumours
Withdrawn NCT00621439 - Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye N/A
Terminated NCT00346372 - Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy
Recruiting NCT03172299 - Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma Phase 3
Completed NCT01893099 - Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma Phase 1
Completed NCT00351728 - Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone N/A
Active, not recruiting NCT03528408 - Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma Phase 2
Completed NCT03052127 - Study in Subjects With Small Primary Choroidal Melanoma Phase 1/Phase 2
Withdrawn NCT01930968 - Definity for Ultrasound of Intraocular Tumors
Recruiting NCT00168870 - Study of Metastatic Ocular Melanoma Phase 2
Completed NCT02519322 - Neoadjuvant and Adjuvant Checkpoint Blockade Phase 2
Recruiting NCT06007690 - A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma Phase 3
Active, not recruiting NCT04417530 - Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma Phase 2
Completed NCT02129075 - A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma Phase 2